The Cost-Benefit Blind Spot: Why Nicotine Regulations Aren't Evaluated for the Harm They Cause
Every nicotine regulation creates winners and losers. The winners are counted (youth protected, smokers deterred). The losers are invisible (smokers who continue smoking because alternatives were restricted). A proper cost-benefit analysis would change policy.
The FDA's PMTA process has authorized 23 vaping products—all from major tobacco companies. The process has eliminated thousands of independent manufacturers and restricted the availability of flavored products that adult smokers used to quit. **How many smokers continued to smoke—and how many of them died—because the PMTA process restricted their access to the products that could have helped them quit? The FDA has never calculated this number. It has counted the benefits of the PMTA process (products evaluated for safety, youth-protective restrictions). It has not counted the costs. The cost-benefit blind spot is a structural feature of nicotine regulation—and it systematically biases policy toward restriction, regardless of the net effect on public health.**
**The blind spot is not unique to the FDA.** The WHO's FCTC advises countries to restrict e-cigarettes but does not require them to evaluate whether those restrictions increase smoking by denying smokers access to alternatives. The state flavor bans that have been implemented across the US have been justified by youth-protection evidence but have not been accompanied by evaluation of their effects on adult smoking. **Nicotine regulation is evaluated by its intended effects (reducing youth use, restricting industry marketing). It is not evaluated by its unintended effects (restricting adult access to harm reduction tools, sustaining the cigarette market). The asymmetry is not evidence-based. It's institutional—the agencies that regulate nicotine are accountable for the harms they prevent, not for the harms they cause.**
**A proper cost-benefit framework would require regulators to estimate both sides of the ledger.** For every restriction: how many youth will be prevented from initiating nicotine use? How many adult smokers will be prevented from switching to reduced-risk products? How many of those adults will continue to smoke—and how many will die as a result? The estimates would be uncertain, model-dependent, and contested—but their existence would change the regulatory calculus. **The cost-benefit blind spot persists because the costs of regulation are invisible and the beneficiaries of the status quo are organized. Making the costs visible—and the beneficiaries of reform audible—is the task of nicotine consumer advocacy.**
**💬 Do you think nicotine regulations should be evaluated by their net effect on public health—including the harm caused by restricting alternatives? How would you estimate the number of smokers who continue smoking because of regulatory barriers to reduced-risk products?**
